Acrivon Therapeutics, Inc. (ACRV)
| Market Cap | 75.76M +81.7% |
| Revenue (ttm) | n/a |
| Net Income | -77.27M |
| EPS | -2.00 |
| Shares Out | 42.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 696,692 |
| Open | 1.900 |
| Previous Close | 1.920 |
| Day's Range | 1.760 - 1.900 |
| 52-Week Range | 1.050 - 3.560 |
| Beta | 2.02 |
| Analysts | Strong Buy |
| Price Target | 11.50 (+549.72%) |
| Earnings Date | May 13, 2026 |
About ACRV
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is AC... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ACRV stock is "Strong Buy." The 12-month stock price target is $11.5, which is an increase of 549.72% from the latest price.
News
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing pr...
Acrivon Therapeutics reports Q1 EPS (49c), consensus (52c)
“2026 is an important catalyst year for Acrivon as we advance our two differentiated, AP3-guided clinical oncology programs towards key data read-outs,” said Peter Blume-Jensen, chief executive office...
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms i...
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of ACR-368 with Topoisomerase 1 (Topo 1) inhibition
Acrivon Therapeutics reports Q4 EPS (49c), consensus (46c)
“It’s an exciting time for the company as we build on strong maturing data and clinical momentum,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.
Acrivon Therapeutics sees cash runway into 2Q27
As of December 31, 2025, the company had cash, cash equivalents and investments of $118.6 million, which is expected to fund operating expenses and capital expenditure requirements into the second…
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC)
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (A...
Acrivon Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
A proteomics-driven platform is advancing targeted cancer therapies, with lead asset ACR-368 showing high response rates and favorable safety in serous endometrial cancer. Rapid global trial expansion and a robust pipeline, including a dual WEE1/PKMYT1 inhibitor and a CDK11 inhibitor, support strong clinical and commercial potential.
Acrivon Therapeutics Transcript: European Society of Gynecological Oncology (ESGO) Congress 2026
ACR-368 showed a 52% response rate and favorable safety in serous endometrial cancer, addressing a major unmet need where current therapies are limited. Experts anticipate broad adoption in second- and third-line settings, with rapid global trial expansion and ongoing FDA engagement for potential accelerated approval.
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing p...
Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
Live webcast of event on February 27 at 8:00 a.m. ET will include participation of globally renowned gynecological oncology KOLs from the US and EU KOL panel to discuss maturing data from the ACR-368 ...
Acrivon Therapeutics announces completion, certification of CLIA certified lab
Acrivon Therapeutics (ACRV) announced the completion and certification of its internal, wholly-owned and operated Clinical Laboratory Improvement Amendment, CLIA, certified laboratory, located on prem...
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
Wholly-owned laboratory has received CLIA certification from Massachusetts with full license to conduct patient testing and develop companion diagnostics Laboratory provides significant operational an...
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
Globally recognized key opinion leader Panagiotis (Panos) Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute, will highlight company's recent interim clinical data from the ongoing, registra...
Acrivon Therapeutics price target raised to $8 from $6 at Piper Sandler
Piper Sandler raised the firm’s price target on Acrivon Therapeutics (ACRV) to $8 from $6 and keeps an Overweight rating on the shares. The firm notes Acrivon hosted a virtual…
Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results
Acrivon Therapeutics’ ($ACRV) shares lost their luster early Thursday despite encouraging results from the biopharma company’s cancer studies. According to the Massachusetts-based drug developer, its ...
Acrivon Therapeutics Transcript: Study Update
The AP3 platform enables precision drug development, with ACR-368 showing high response rates in serous endometrial cancer and a favorable safety profile. ACR-2316 demonstrates activity in aggressive lung cancers, and preclinical ACR-6840 targets CDK11. IND for ACR-6840 is planned for Q4.
Acrivon Therapeutics announces progress across pipeline
Acrivon Therapeutics (ACRV) announced significant progress across its pipeline, including updates regarding the Phase 2 ACR-368 program, initial clinical data from the ACR-2316 Phase 1 study, and the ...
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall...
Acrivon Therapeutics to announce clinical update on Phase 2b ACR-368 studies
Acrivon Therapeutics (ACRV) will be providing ACR-368 and ACR-2316 clinical data and other updates via a press release at 7:30 a.m. ET, and conference call and webcast at 8:30 a.m.
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026 Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing p...
Acrivon to provide ACR-368, ACR-2316 clinical data in January
Acrivon Therapeutics (ACRV) will be providing ACR-368 and ACR-2316 clinical data and other updates in January 2026. Topics will include: Updated interim ACR-368 clinical data from the ongoing registra...
Acrivon Therapeutics reports Q3 EPS (47c), consensus (58c)
“Our team continues to efficiently advance our AP3-enabled pipeline of targeted agents, maintaining strong momentum over the past quarter,” said Peter Blume-Jensen, chief executive officer, president,...